A Self‐Catalytic NO/O2 Gas‐Releasing Nanozyme for Radiotherapy Sensitization through Vascular Normalization and Hypoxia Relief
- 5 August 2024
- journal article
- research article
- Published by Wiley in Advanced Materials
- Vol. 36 (39) , e2403921
Abstract
Radiotherapy (RT), essential for treating various cancers, faces challenges from tumor hypoxia, which induces radioresistance. A tumor‐targeted “prosthetic‐Arginine” coassembled nanozyme system, engineered to catalytically generate nitric oxide (NO) and oxygen (O2) in the tumor microenvironment (TME), overcoming hypoxia and enhancing radiosensitivity is presented. This system integrates the prosthetic heme of nitric oxide synthase (NOS) and catalase (CAT) with NO‐donating Fmoc‐protected Arginine and Ru3+ ions, creating HRRu nanozymes that merge NOS and CAT functionalities. Surface modification with human heavy chain ferritin (HFn) improves the targeting ability of nanozymes (HRRu‐HFn) to tumor tissues. In the TME, strategic arginine incorporation within the nanozyme allows autonomous O2 and NO release, triggered by endogenous hydrogen peroxide, elevating NO and O2 levels to normalize vasculature and improve blood perfusion, thus mitigating hypoxia. Employing the intrinsic O2‐transporting ability of heme, HRRu‐HFn nanozymes also deliver O2 directly to the tumor site. Utilizing esophageal squamous cell carcinoma as a tumor model, the studies reveal that the synergistic functions of NO and O2 production, alongside targeted delivery, enable the HRRu‐HFn nanozymes to combat tumor hypoxia and potentiate radiotherapy. This HRRu‐HFn nanozyme based approach holds the potential to reduce the radiation dose required and minimize side effects associated with conventional radiotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (32000996, 82122037, 22367013)
- China Postdoctoral Science Foundation (2020M682358)
- Natural Science Foundation of Jiangxi Province (20212BAB213019)
- University of Tokyo (2019‐K3005)
This publication has 81 references indexed in Scilit:
- Multistage‐Responsive Dual‐Enzyme Nanocascades for Synergistic Radiosensitization‐Starvation Cancer TherapyAdvanced Healthcare Materials, 2023
- Advances in the Theranostics of Oesophageal Squamous CarcinomaAdvanced Therapeutics, 2023
- Application of nano‐radiosensitizers in combination cancer therapyBioengineering & Translational Medicine, 2023
- Supramolecular Nitric Oxide Depot for Hypoxic Tumor Vessel Normalization and RadiosensitizationAdvanced Materials, 2022
- Biomimetic Nanozymes Based on Coassembly of Amino Acid and Hemin for Catalytic Oxidation and Sensing of BiomoleculesSmall, 2021
- NIR Light‐Driven Bi2Se3‐Based Nanoreactor with “Three in One” Hemin‐Assisted Cascade Catalysis for Synergetic Cancer TherapyAdvanced Functional Materials, 2020
- Self‐Assembling Endogenous Biliverdin as a Versatile Near‐Infrared Photothermal Nanoagent for Cancer TheranosticsAdvanced Materials, 2019
- Recent Advances in Functional‐Polymer‐Decorated Transition‐Metal Nanomaterials for Bioimaging and Cancer TherapyChemMedChem, 2018
- Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalizeJournal of Cellular Biochemistry, 2006
- The role of radiotherapy in cancer treatmentCancer, 2005